IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies ...

This poster presents the impact of the PCK1 gene on TIIDM incidence in Oji-Cree Natives with particular attention to the role of SNP 232C→G on the transcription rate of phosphoenolpyruvate ...

This poster discusses the use of ChipCytometry, a modified approach to slide-based cytometry, which is a novel, highly multiplexed technology that preserves both plex and spatial context to deeply ...

Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety ...

One poster demonstrating cell-free DNA molecular response as a potential surrogate endpoint to measure clinical efficacy of azenosertib in ...

Several tumour-suppressor proteins monitor intrinsic and extrinsic signals and integrate these inputs to decide whether the cell should remain in a quiescent state or enter into the cycle of ...

Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today ...

C.A. Details of the poster presentation are as follows: Abstract Title: ADI-270, an Armored Allogeneic Anti-CD70 γδ CAR T Cell Therapy, Demonstrates Improved Efficacy and Safety in Preclinical ...

“Among these, we are excited to share updates on ZW209, our DLL3-targeting trispecific T cell engager incorporating co-stimulation, which is on track for IND submission in 1H-2026, and ...

Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety profile New antibody-drug conjugate (ADC) candidate, ZW327 ...

Update on IND-enabling data for MP0712, a Radio-DARPin targeting DLL3 and labeled with 212Pb, co-developed with Orano Med; entering FIH studies in 2025 for the treatment of small cell lung cancer Firs ...